J2267 Injection, mirikizumab-mrkz, 1 milligrams
Also known as: mirikizumab, IL-23 antibody
Injection of mirikizumab-mrkz, 1 milligram. A monoclonal antibody targeting interleukin-23 for inflammatory bowel disease.
In Plain Language
inflammatory bowel disease medication; immune-targeting antibody
Clinical Context
Used for moderately to severely active ulcerative colitis. Mirikizumab targets IL-23 receptor to reduce intestinal inflammation.
RVU Information
CPT J2267 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J2267?
CPT J2267 (Injection, mirikizumab-mrkz, 1 milligrams) is a J Codes (Drugs) code. Injection of mirikizumab-mrkz, 1 milligram. A monoclonal antibody targeting interleukin-23 for inflammatory bowel disease.
How is J2267 administered?
CPT J2267 is administered by a healthcare provider, typically via injection or infusion. Used for moderately to severely active ulcerative colitis. Mirikizumab targets IL-23 receptor to reduce intestinal inflammation. It is used by Gastroenterology, Immunology.
When is CPT J2267 used?
Used for moderately to severely active ulcerative colitis. Mirikizumab targets IL-23 receptor to reduce intestinal inflammation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.